Tuesday, 22 October 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 22 October 2024
News

Antiviral withdrawn from TGA

Posted 21 October 2024 AM

Starpharma has thrown in the towel on registering its broad-spectrum antiviral nasal spray Viraleze on the ARTG.

The pharma has been seeking registration for three years, since the spray was shown to have efficacy against Covid. Rather than any concern about safety or effectiveness, in 2022 the SMH reported the sticking point was the TGA believing the nasal spray should be registered as a medicine, while Starpharma insisted it should be as a medical device.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (15)

Access & Reimbursement (1)

Clinical & Medical, R&D (18)

Regulatory, Pharmacovigilance & QA (4)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.